Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Micafungin Elicits an Immunomodulatory Effect in Galleria mellonella and Mice.

Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G, Rajamuthiah R, Mylonakis E.

Mycopathologia. 2016 Feb;181(1-2):17-25. doi: 10.1007/s11046-015-9940-z. Epub 2015 Sep 18. Erratum in: Mycopathologia. 2016 Feb;181(1-2):27.


Caspofungin primes the immune response of the larvae of Galleria mellonella and induces a non-specific antimicrobial response.

Kelly J, Kavanagh K.

J Med Microbiol. 2011 Feb;60(Pt 2):189-96. doi: 10.1099/jmm.0.025494-0. Epub 2010 Oct 14.


In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.

Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.


The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice.

Kissoyan KA, Bazzi W, Hadi U, Matar GM.

Biofouling. 2016 Aug;32(7):779-86. doi: 10.1080/08927014.2016.1199021.


Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83. doi: 10.1128/AAC.01686-10. Epub 2011 Apr 18.


Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Rueda C, Cuenca-Estrella M, Zaragoza O.

Antimicrob Agents Chemother. 2014;58(2):1071-83. doi: 10.1128/AAC.00946-13. Epub 2013 Dec 2.


Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.

Niimi K, Monk BC, Hirai A, Hatakenaka K, Umeyama T, Lamping E, Maki K, Tanabe K, Kamimura T, Ikeda F, Uehara Y, Kano R, Hasegawa A, Cannon RD, Niimi M.

J Antimicrob Chemother. 2010 May;65(5):842-52. doi: 10.1093/jac/dkq073. Epub 2010 Mar 16.


An immunomodulatory activity of micafungin in preclinical aspergillosis.

Moretti S, Bozza S, Massi-Benedetti C, Prezioso L, Rossetti E, Romani L, Aversa F, Pitzurra L.

J Antimicrob Chemother. 2014 Apr;69(4):1065-74. doi: 10.1093/jac/dkt457. Epub 2013 Nov 20.


[Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].

Catalán-González M, Carlos Montejo-González J.

Rev Iberoam Micol. 2009 Mar 31;26(1):23-34. doi: 10.1016/S1130-1406(09)70005-1. Epub 2009 May 7. Review. Spanish. Erratum in: Rev Iberoam Micol. 2009 Jun 30;26(2):166..


Micafungin: a sulfated echinocandin.

Hashimoto S.

J Antibiot (Tokyo). 2009 Jan;62(1):27-35. doi: 10.1038/ja.2008.3. Epub 2009 Jan 9.


In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506. doi: 10.1128/AAC.01584-09. Epub 2010 Apr 12.


Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates.

Nguyen KT, Ta P, Hoang BT, Cheng S, Hao B, Nguyen MH, Clancy CJ.

Int J Antimicrob Agents. 2010 Jan;35(1):80-4. doi: 10.1016/j.ijantimicag.2009.09.003. Epub 2009 Nov 4.


Micafungin alters the expression of genes related to cell wall integrity in Candida albicans biofilms.

Kaneko Y, Ohno H, Kohno S, Miyazaki Y.

Jpn J Infect Dis. 2010 Sep;63(5):355-7.


Breakthrough invasive candidiasis in patients on micafungin.

Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD.

J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.


Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

Guembe M, Guinea J, Marcos-Zambrano LJ, Fernández-Cruz A, Peláez T, Muñoz P, Bouza E.

Antimicrob Agents Chemother. 2014 Sep;58(9):5581-4. doi: 10.1128/AAC.02738-14. Epub 2014 Jun 23.


Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.

Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW.

Antimicrob Agents Chemother. 2015 Sep;59(9):5405-12. doi: 10.1128/AAC.00624-15. Epub 2015 Jun 22.


Immunomodulatory effects of voriconazole and caspofungin on human peripheral blood mononuclear cells stimulated by Candida albicans and Candida krusei.

Fidan I, Yesilyurt E, Kalkanci A, Aslan SO, Sahin N, Ogan MC, Dizbay M.

Am J Med Sci. 2014 Sep;348(3):219-23. doi: 10.1097/MAJ.0000000000000236.


Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.

Gil-Alonso S, Jauregizar N, Eraso E, Quindós G.

PLoS One. 2015 Jul 13;10(7):e0132730. doi: 10.1371/journal.pone.0132730. eCollection 2015.


Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods.

Cantón E, Pemán J, Hervás D, Espinel-Ingroff A.

J Antimicrob Chemother. 2013 Apr;68(4):864-8. doi: 10.1093/jac/dks489. Epub 2012 Dec 9.


Supplemental Content

Support Center